Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Vivaldi Coelho Rogerio, Chairman & CEO. Director active across 3 companies, notably Sigilon Therapeutics, Inc.. In total, 12 disclosures have been logged. Split: 1 buy · 2 sells. Total volume traded: €347k. History available since 4 November 2021. The latest transaction was disclosed on 2 July 2026 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Rogerio Vivaldi Coelho is the President and CEO of Sigilon Therapeutics, Inc. In this role, he oversees all operations of the company and is responsible for overall strategy. His leadership is essential for guiding the company's direction and achieving its growth objectives.